Prothena Corp Public (PRTA) Net Income (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Net Income of $32.7 million for Q1 2026, up 154.36% year-over-year from $12.9 million in Q1 2025, and up 251.89% quarter-over-quarter from -$21.5 million in Q4 2025.
Analysis
Prothena Corp Public (PRTA) Net Income (2012 - 2026) Analysis & Trends
Prothena Corp Public's Net Income history runs 15 years deep, the most recent figure standing at $32.7 million for Q1 2026.
- In Q1 2026, Net Income rose 154.36% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at -$151.1 million (down 36.91% YoY), while the FY2025 annual figure was -$244.1 million, down 99.57% from the prior year.
- Net Income for Q1 2026 stood at $32.7 million, up from -$21.5 million in the prior quarter.
- The five-year high for Net Income was $66.8 million in Q2 2024, with the low at -$125.8 million in Q2 2025.
- The 5-year median for Net Income is -$45.7 million (2022), against an average of -$35.2 million.
- The sharpest annual moves came in 2023 and 2024: Net Income sank 1162.78% in 2023, then jumped 222.43% in 2024.
- Prothena Corp Public's Net Income stood at $6.3 million in 2022, then tumbled by 1162.78% to -$67.5 million in 2023, then increased by 14.07% to -$58.0 million in 2024, then surged by 62.85% to -$21.5 million in 2025, then soared by 251.89% to $32.7 million in 2026.
- Business Quant data shows PRTA's Net Income at $32.7 million in Q1 2026, -$21.5 million in Q4 2025, and -$36.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Prothena Corp Public | 509.98 Mn | 221.78 Mn | - | -18.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18.58 Mn |
| Mar 31, 2026 | 32.72 Mn |
| Dec 31, 2025 | -21.54 Mn |
| Sep 30, 2025 | -36.51 Mn |
| Jun 30, 2025 | -125.77 Mn |
| Mar 31, 2025 | -60.17 Mn |
| Dec 31, 2024 | -57.98 Mn |
| Sep 30, 2024 | -59.00 Mn |
| Jun 30, 2024 | 66.89 Mn |
| Mar 31, 2024 | -72.24 Mn |
| Dec 31, 2023 | -67.48 Mn |
| Sep 30, 2023 | 21.92 Mn |
| Jun 30, 2023 | -54.60 Mn |
| Mar 31, 2023 | -46.86 Mn |
| Dec 31, 2022 | 6.30 Mn |
| Sep 30, 2022 | -45.72 Mn |
| Jun 30, 2022 | -41.24 Mn |
| Mar 31, 2022 | -36.26 Mn |
| Dec 31, 2021 | -33.14 Mn |
| Sep 30, 2021 | 109.25 Mn |